Guideways, the Dutch AI firm serving to MedTech innovators navigate regulatory and compliance complexity, has raised over €1 million in pre-Seed financing in accordance with a supply near the spherical.
The funding got here from HealthTech funds Wholesome.Capital and Rising Star Enterprise Companions and shall be used to launch and scale Guideways’ agentic AI platform, constructed to assist medical gadget corporations obtain regulatory approval and produce lifesaving applied sciences to sufferers years sooner.
Alexander Habermeier, co-founder of Guideways: “At Guideways, our mission is easy: get 10 occasions extra life-changing improvements to sufferers, sooner and even safer. We’re thrilled to have efficiently closed our pre-Seed funding spherical. This funding will speed up the event of our groundbreaking AI platform and empower MedTech innovators to ship their life-saving new applied sciences to sufferers months, and even years, sooner.”
In context: This pre-Seed funding Guideways aligns with a broader 2025 pattern throughout Europe the place AI and automation are being utilized to regulatory and compliance challenges in MedTech.
In April 2025, REMATIQ (Berlin) raised €5.4 million to advance its AI-native platform for automated product compliance, highlighting investor confidence in instruments that streamline regulatory workflows. Earlier within the yr, Mulder secured €597k in pre-Seed funding to develop a medical-device traceability platform.
Whereas each REMATIQ and Mulder function in adjoining compliance and traceability niches, Guideways stands out for its give attention to agentic AI constructed particularly for regulatory approval processes – initially focusing on U.S. FDA pathways earlier than increasing to European MDR frameworks.
Douwe Jippes, Co-founder and Managing accomplice at Wholesome.Capital: “The crew at Guideways has a deep, private understanding of the issue they’re fixing. They assist corporations to convey improvements to market sooner and extra efficiently by considerably decreasing the approval time and prices, basically altering how medical gadgets are delivered to market. This makes healthcare innovation extra accessible and environment friendly, which completely aligns with our mission at Wholesome.Capital to make healthcare reasonably priced and accessible.”
Based in 2024, Guideways develops AI brokers that “minimize via regulatory approval, compliance, and reimbursement complexity” for MedTech innovators.
With greater than 37 years of mixed MedTech expertise, the founding crew has seen first-hand how regulatory hurdles derail promising improvements. Guideways’ platform goals to automate essentially the most time-consuming elements of compliance via a collection of specialized AI brokers, centered initially on the U.S. FDA approval course of:
-
FDA Sherpa: guides groups from an idea description to an in depth approval technique, figuring out the proper classification, pathway, necessities, and requirements.
-
FDA Reviewer: performs in-depth checks of regulatory submissions, reviewing a whole bunch of paperwork for compliance and suggesting fixes.
-
FDA Researcher: permits natural-language exploration of a data base of greater than 150,000 reference paperwork, combining data intelligently to reply complicated queries.
Saskia ten Siethoff, QA/RA Specialist, Flux Robotics added: “Utilizing Guideways’ FDA Sherpa helped us shortly outline our supposed use and map out the best FDA pathway for our next-generation vascular surgical procedure robotic. It not solely saved time but in addition defined the reasoning behind its suggestions; one thing that actually constructed confidence to navigate complicated rules.”
Yearly, tens of 1000’s of promising medical applied sciences are slowed down by the complexity of regulation, high quality and reimbursement. In keeping with knowledge supplied by the corporate, processes right this moment devour as much as 75% of MedTech growth prices and may delay market entry by 31 to 66 months.
Behind these delays are sufferers ready for higher care.
Martijn van de Giessen, CEO, Secuped: “As a MedTech firm, regulatory necessities have an unlimited influence on our technique and highway to market. Guideways made it straightforward and accessible for us to shortly assess the place we stand and learn how to proceed.”
The brand new funding will assist business launch actions, ongoing platform growth, and enlargement towards European MDR and reimbursement frameworks in 2026.
Benjamin Sieters, Funding Director at Rising Star Enterprise Companions added: “Guideways is a chief instance of an organization with the potential for quick and big influence. By addressing limitations throughout the innovation pipeline, the corporate empowers well being know-how innovators to succeed and produce their options sooner and extra cost-effectively to a world market.
“Now we have seen first-hand how Guideways’ platform can reliably fast-track difficult and costly steps within the crucial path to regulatory approval, compliance and reimbursement. We’re proud to again their mission to speed up the supply of groundbreaking medical applied sciences.“

